Linked Life Data

1353901

Source:http://linkedlifedata.com/resource/pubmed/id/1353901

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1992-9-9
pubmed:abstractText
Sulphasalazine is among the many drugs in the secondary line of antirheumatic efficacy that have both immunosuppressive and auto-inflammatory properties. Twenty-six patients with definite rheumatoid arthritis (RA) were treated for two years with sulphasalazine in a minimum dose of 1 g per day. Four patients presented untoward effects such as: marked physical asthenia, erythema and changes of the dysproteinemia tests which all disappeared when the drug was withdrawn. The first favourable results in the joint inflammation appeared after 4 weeks. Significant clinical and biologic changes were observed at the end of the study thus suggesting the therapeutic value of sulphasalazine in RA.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1220-4749
pubmed:author
pubmed:issnType
Print
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
127-32
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Sulphasalazine therapy in rheumatoid arthritis. A two-year study and follow-up of clinical results.
pubmed:affiliation
N. Gh. Lupu Institute of Internal Medicine, Bucharest, Romania.
pubmed:publicationType
Journal Article